SlideShare une entreprise Scribd logo
1  sur  81
Hypertension Physiology, Pathophysiology and Clinical Managements Jun  Tao
Stroke and Ischemic Heart Disease (IHD) Mortality Rate in Each Decade of Age, Versus Usual Systolic BP at the Start of that Decade Mortality* Usual SBP (mmHg) 50–59 y 60–69 y 70–79 y 80–89 y Stroke Age at risk 256 128 64 32 16 8 4 2 1 0 120 140 160 180 IHD Usual SBP (mmHg ) 50–59 y 60–69 y 70–79 y 80–89 y Age at risk 40–49 y 256 128 64 32 16 8 4 2 1 0 120 140 160 180 *Floating absolute risk and 95% CI Reproduced from The Lancet, 360, Lewington et al. pp. 1903–13 Copyright  © 2002, with permission from Elsevier
Introduction ,[object Object]
[object Object]
[object Object]
Primary hypertension
Etiology and pathogenesis ,[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pathology ,[object Object]
Blood vessel change ,[object Object],[object Object]
[object Object]
 
[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object]
Specific organ changes in hypertension ,[object Object],[object Object]
[object Object]
Hpertrophy of left ventricle
 
[object Object],[object Object]
[object Object]
 
 
[object Object],[object Object]
[object Object]
肾动脉硬化 肾动脉硬化 致密的肾盂 X 线影象
Malignant hypertension:  Fibrinoid necrosis of damaged arteriole of kidney
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
Symptoms ,[object Object],[object Object]
[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Symptoms associated with target organ damage ,[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
Complications  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
physical examination  ,[object Object],[object Object],[object Object]
Diagnosis  ,[object Object]
 
CVD Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],*Components of the metabolic syndrome.
Cardiovascular risk category of hypertension   Blood pressure ( mmHg )   Grade 1(SBP 140 ~ 159 or DBP 90 ~ 99)  Grade 2(SBP 160 ~ 179 or DBP 100 ~ 109) Grade 3(SBP ≥180 or DBP ≥110) No other risk factors Low-risk   Medium-risk High-risk   1 ~ 2  risk factors Moderate-risk   Medium-risk Very High-risk 3 or more  risk factors   , or diabetes , or target organ damage High-risk   High-risk   Very High-risk complications Very High-risk Very High-risk Very High-risk
Laboratory examinations ,[object Object],[object Object],[object Object]
Goals of Therapy ,[object Object],[object Object],[object Object]
Blood Pressure Reduction of 2 mmHg Decreases the Risk of Cardiovascular Events by 7–10% ,[object Object],[object Object],[object Object],2 mmHg decrease in mean SBP 10% reduction in risk of stroke mortality 7% reduction in risk of ischaemic heart disease mortality Lewington et al. Lancet 2002;360:1903–13
Lifestyle Modification ,[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
Algorithm for Treatment of Hypertension Not at Goal Blood Pressure (<140/90 mmHg)  (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications  Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB)  as needed.  With Compelling  Indications Stage 2 Hypertension   (SBP  > 160 or DBP  > 100 mmHg)  2-drug combination for most (usually thiazide-type diuretic and  ACEI, or ARB, or BB, or CCB) Stage 1 Hypertension (SBP 140–159 or DBP 90–99 mmHg)  Thiazide-type diuretics for most.  May consider ACEI, ARB, BB, CCB,  or combination. Without Compelling  Indications Not at Goal  Blood Pressure Optimize dosages or add additional drugs  until goal blood pressure is achieved. Consider consultation with hypertension specialist.
Drug treatment  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],,
 
 
Classification and Management  of BP for adults *Treatment determined by highest BP category. † Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension. ‡ Treat patients with chronic kidney disease or diabetes to BP goal of <130/80 mmHg.  BP classification   SBP* mmHg   DBP* mmHg  Lifestyle modification   Initial drug therapy   Without compelling indication  With compelling indications Normal  <120  and <80  Encourage  Prehypertension  120–139  or 80–89  Yes  No antihypertensive drug indicated.  Drug(s) for compelling indications.  ‡   Stage 1 Hypertension  140–159  or 90–99  Yes  Thiazide-type diuretics for most.  May consider ACEI, ARB, BB, CCB, or combination.  Drug(s) for the compelling indications. ‡ Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed.  Stage 2 Hypertension  > 160  or  > 100  Yes  Two-drug combination for most †  (usually thiazide-type diuretic and ACEI or ARB or BB or CCB).
 
 
Other medications for hypertensive patients Primary prevention ( 1 ) Aspirin: use 75mg daily if patient is aged   50 years with blood pressure controlled to <150/90 mm Hg and either; target organ damage, diabetes mellitus, or 10 year risk of cardiovascular disease of   20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) ( 2 ) Statin: use sufficient doses to reach targets if patient is aged up to at least 80 years, with a 10 year risk of cardiovascular disease of   20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) and with total cholesterol concentration   3.5mmol/l ( 3 ) Vitamins—no benefit shown, do not prescribe
[object Object],[object Object],[object Object],[object Object],[object Object],Other medications for hypertensive patients
Targets for lipid lowering Ideal - TC<4.0mmol/l or LDL <2.0mmol/l or 25%    in TC or 30%    in LDL-C whichever is the greater ‘ Audit’ - TC <5.0mmol/l or LDL <3.0mmol/l or 25%    in TC or 30%    in LDL-C whichever is the greater Lipid targets
[object Object]
CVD Risk Factors ,[object Object],[object Object],[object Object]
Target organ damage ,[object Object],[object Object],[object Object],[object Object],[object Object]
ESH - ESC Guidelines, J Hypertens 2008 -BP < 140/90 mmHg in all hypertensive patients < 130/80 mmHg in hypertensive patients  with diabetes or renal disease -Control of all cardiovascular risk factors Goals of treatment
About drug treatment ,[object Object],[object Object],[object Object]
Screening and treatment of secondary forms of hypertension ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
谢谢!

Contenu connexe

Tendances

Hypertension pathophysiology
Hypertension   pathophysiologyHypertension   pathophysiology
Hypertension pathophysiologyHariHaran342
 
HYPERTENSION
HYPERTENSIONHYPERTENSION
HYPERTENSIONHIRANGER
 
ECG Changes in Myocardial Infarction
ECG Changes in Myocardial InfarctionECG Changes in Myocardial Infarction
ECG Changes in Myocardial InfarctionAdeboye Oluwajuyitan
 
Hypertension-Pathophysiology, Treatment of hypertension, Diagnosis with AntiH...
Hypertension-Pathophysiology, Treatment of hypertension, Diagnosis with AntiH...Hypertension-Pathophysiology, Treatment of hypertension, Diagnosis with AntiH...
Hypertension-Pathophysiology, Treatment of hypertension, Diagnosis with AntiH...varinder kumar
 
Hypertension, its causes, types and management
Hypertension, its causes, types and managementHypertension, its causes, types and management
Hypertension, its causes, types and managementAbu Bakar
 
Electrocardiogaram - ECG EKG
Electrocardiogaram - ECG EKGElectrocardiogaram - ECG EKG
Electrocardiogaram - ECG EKGFuad Farooq
 
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...Chetan Ganteppanavar
 
Hypertension update 2018
Hypertension update 2018Hypertension update 2018
Hypertension update 2018Mahfuzul Islam
 
Cardiovascular Disease.ppt
Cardiovascular Disease.pptCardiovascular Disease.ppt
Cardiovascular Disease.pptShama
 

Tendances (20)

Hypertension pathophysiology
Hypertension   pathophysiologyHypertension   pathophysiology
Hypertension pathophysiology
 
HYPERTENSION
HYPERTENSIONHYPERTENSION
HYPERTENSION
 
Hypertension
Hypertension Hypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
 
Hypertension
HypertensionHypertension
Hypertension
 
ECG Changes in Myocardial Infarction
ECG Changes in Myocardial InfarctionECG Changes in Myocardial Infarction
ECG Changes in Myocardial Infarction
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension lecture
Hypertension lecture Hypertension lecture
Hypertension lecture
 
Hypertension-Pathophysiology, Treatment of hypertension, Diagnosis with AntiH...
Hypertension-Pathophysiology, Treatment of hypertension, Diagnosis with AntiH...Hypertension-Pathophysiology, Treatment of hypertension, Diagnosis with AntiH...
Hypertension-Pathophysiology, Treatment of hypertension, Diagnosis with AntiH...
 
Hypertension, its causes, types and management
Hypertension, its causes, types and managementHypertension, its causes, types and management
Hypertension, its causes, types and management
 
Hypertention ppt
Hypertention pptHypertention ppt
Hypertention ppt
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 
HF update 2021
HF update 2021HF update 2021
HF update 2021
 
Electrocardiogaram - ECG EKG
Electrocardiogaram - ECG EKGElectrocardiogaram - ECG EKG
Electrocardiogaram - ECG EKG
 
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
Secondary hypertension - Etiopathogenesis, Clinical features, Advances in Man...
 
Hypertension update 2018
Hypertension update 2018Hypertension update 2018
Hypertension update 2018
 
Cardiovascular Disease.ppt
Cardiovascular Disease.pptCardiovascular Disease.ppt
Cardiovascular Disease.ppt
 
Diabetic nephropathy
Diabetic nephropathyDiabetic nephropathy
Diabetic nephropathy
 

En vedette

Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathyfitango
 
Cardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failureCardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failureayeayetun08
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.pptShama
 
Pulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephDr.Tinku Joseph
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases pptUma Binoy
 
VALVULAR HEART DISEASE
VALVULAR HEART DISEASEVALVULAR HEART DISEASE
VALVULAR HEART DISEASEhanisahwarrior
 

En vedette (11)

Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 
Cardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failureCardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failure
 
Cardiomyopathies
CardiomyopathiesCardiomyopathies
Cardiomyopathies
 
Ischemic Heart Disease
Ischemic Heart DiseaseIschemic Heart Disease
Ischemic Heart Disease
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.ppt
 
Pulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku joseph
 
Heart Disease
Heart DiseaseHeart Disease
Heart Disease
 
Valvular heart disease and anaesthesia
Valvular heart disease and anaesthesiaValvular heart disease and anaesthesia
Valvular heart disease and anaesthesia
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases ppt
 
Heart disease
Heart disease Heart disease
Heart disease
 
VALVULAR HEART DISEASE
VALVULAR HEART DISEASEVALVULAR HEART DISEASE
VALVULAR HEART DISEASE
 

Similaire à 10 hypertension (20)

HYPERTENSION
HYPERTENSIONHYPERTENSION
HYPERTENSION
 
Hypertension
HypertensionHypertension
Hypertension
 
1. Hypertension (2).pptx
1. Hypertension (2).pptx1. Hypertension (2).pptx
1. Hypertension (2).pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)
L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)
L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension (htn)
Hypertension (htn)Hypertension (htn)
Hypertension (htn)
 
hypertension.pptx
hypertension.pptxhypertension.pptx
hypertension.pptx
 
Hypertension - Approach & Management
Hypertension - Approach & ManagementHypertension - Approach & Management
Hypertension - Approach & Management
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Lecture 8 hypertension - Pathology
Lecture 8 hypertension - Pathology Lecture 8 hypertension - Pathology
Lecture 8 hypertension - Pathology
 
PATHOLOGY OF HYPERTENSION .ppt
PATHOLOGY OF HYPERTENSION           .pptPATHOLOGY OF HYPERTENSION           .ppt
PATHOLOGY OF HYPERTENSION .ppt
 
Essential hypertension management and treatment
Essential hypertension management  and treatmentEssential hypertension management  and treatment
Essential hypertension management and treatment
 
HYPERTENSION (4).ppt
HYPERTENSION (4).pptHYPERTENSION (4).ppt
HYPERTENSION (4).ppt
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Management of hypertensive crisis
Management of hypertensive crisisManagement of hypertensive crisis
Management of hypertensive crisis
 

Plus de internalmed

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusinternalmed
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeinternalmed
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文internalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhouinternalmed
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular diseaseinternalmed
 
23 renal disease
23 renal disease23 renal disease
23 renal diseaseinternalmed
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitisinternalmed
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitisinternalmed
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathyinternalmed
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosisinternalmed
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial diseaseinternalmed
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gaointernalmed
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009internalmed
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 

Plus de internalmed (20)

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhou
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular disease
 
23 renal disease
23 renal disease23 renal disease
23 renal disease
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitis
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitis
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathy
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosis
 
18 peptic ulcer
18 peptic ulcer18 peptic ulcer
18 peptic ulcer
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial disease
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gao
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 

Dernier

Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Jisc
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxDr. Ravikiran H M Gowda
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfDr Vijay Vishwakarma
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17Celine George
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptxMaritesTamaniVerdade
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxmarlenawright1
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibitjbellavia9
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jisc
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsMebane Rash
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxEsquimalt MFRC
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.christianmathematics
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxDr. Sarita Anand
 

Dernier (20)

Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 

10 hypertension

  • 1. Hypertension Physiology, Pathophysiology and Clinical Managements Jun Tao
  • 2. Stroke and Ischemic Heart Disease (IHD) Mortality Rate in Each Decade of Age, Versus Usual Systolic BP at the Start of that Decade Mortality* Usual SBP (mmHg) 50–59 y 60–69 y 70–79 y 80–89 y Stroke Age at risk 256 128 64 32 16 8 4 2 1 0 120 140 160 180 IHD Usual SBP (mmHg ) 50–59 y 60–69 y 70–79 y 80–89 y Age at risk 40–49 y 256 128 64 32 16 8 4 2 1 0 120 140 160 180 *Floating absolute risk and 95% CI Reproduced from The Lancet, 360, Lewington et al. pp. 1903–13 Copyright © 2002, with permission from Elsevier
  • 3.
  • 4.
  • 5.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.  
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26. Hpertrophy of left ventricle
  • 27.  
  • 28.
  • 29.
  • 30.  
  • 31.  
  • 32.
  • 33.
  • 35. Malignant hypertension: Fibrinoid necrosis of damaged arteriole of kidney
  • 36.
  • 37.  
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.  
  • 51.
  • 52. Cardiovascular risk category of hypertension   Blood pressure ( mmHg ) Grade 1(SBP 140 ~ 159 or DBP 90 ~ 99) Grade 2(SBP 160 ~ 179 or DBP 100 ~ 109) Grade 3(SBP ≥180 or DBP ≥110) No other risk factors Low-risk Medium-risk High-risk 1 ~ 2 risk factors Moderate-risk Medium-risk Very High-risk 3 or more risk factors , or diabetes , or target organ damage High-risk High-risk Very High-risk complications Very High-risk Very High-risk Very High-risk
  • 53.
  • 54.
  • 55.
  • 56.
  • 57.
  • 58.
  • 59. Algorithm for Treatment of Hypertension Not at Goal Blood Pressure (<140/90 mmHg) (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. With Compelling Indications Stage 2 Hypertension (SBP > 160 or DBP > 100 mmHg) 2-drug combination for most (usually thiazide-type diuretic and ACEI, or ARB, or BB, or CCB) Stage 1 Hypertension (SBP 140–159 or DBP 90–99 mmHg) Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Without Compelling Indications Not at Goal Blood Pressure Optimize dosages or add additional drugs until goal blood pressure is achieved. Consider consultation with hypertension specialist.
  • 60.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.
  • 66.
  • 67.  
  • 68.  
  • 69. Classification and Management of BP for adults *Treatment determined by highest BP category. † Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension. ‡ Treat patients with chronic kidney disease or diabetes to BP goal of <130/80 mmHg. BP classification SBP* mmHg DBP* mmHg Lifestyle modification Initial drug therapy Without compelling indication With compelling indications Normal <120 and <80 Encourage Prehypertension 120–139 or 80–89 Yes No antihypertensive drug indicated. Drug(s) for compelling indications. ‡ Stage 1 Hypertension 140–159 or 90–99 Yes Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Drug(s) for the compelling indications. ‡ Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. Stage 2 Hypertension > 160 or > 100 Yes Two-drug combination for most † (usually thiazide-type diuretic and ACEI or ARB or BB or CCB).
  • 70.  
  • 71.  
  • 72. Other medications for hypertensive patients Primary prevention ( 1 ) Aspirin: use 75mg daily if patient is aged  50 years with blood pressure controlled to <150/90 mm Hg and either; target organ damage, diabetes mellitus, or 10 year risk of cardiovascular disease of  20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) ( 2 ) Statin: use sufficient doses to reach targets if patient is aged up to at least 80 years, with a 10 year risk of cardiovascular disease of  20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) and with total cholesterol concentration  3.5mmol/l ( 3 ) Vitamins—no benefit shown, do not prescribe
  • 73.
  • 74. Targets for lipid lowering Ideal - TC<4.0mmol/l or LDL <2.0mmol/l or 25%  in TC or 30%  in LDL-C whichever is the greater ‘ Audit’ - TC <5.0mmol/l or LDL <3.0mmol/l or 25%  in TC or 30%  in LDL-C whichever is the greater Lipid targets
  • 75.
  • 76.
  • 77.
  • 78. ESH - ESC Guidelines, J Hypertens 2008 -BP < 140/90 mmHg in all hypertensive patients < 130/80 mmHg in hypertensive patients with diabetes or renal disease -Control of all cardiovascular risk factors Goals of treatment
  • 79.
  • 80.

Notes de l'éditeur

  1. These data are taken from a meta-analysis of 61 prospective observational studies on deaths from vascular disease among subjects without vascular disease at baseline. The results demonstrated that the relationship of stroke mortality (left panel) and ischemic heart disease (IHD) mortality (right panel) to usual BP is strong and direct at all ages. As highlighted on the following slide, each difference of 20 mmHg in usual systolic BP is associated with a two-fold difference in the risk of stroke mortality and IHD mortality (between ages 40–69 years). The annual absolute difference in risk is greater in old age. Reference Lewington S, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.
  2. Trials have shown that BP lowering can produce rapid reductions in cardiovascular disease risk. In fact, even a 2 mmHg decrease in systolic BP would result in approximately 7% lower mortality risk from ischemic heart disease and a 10% lower mortality risk from stroke. Reference Lewington S, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.
  3. bhs guidelines 2004.boeh-ingel
  4. bhs guidelines 2004.boeh-ingel
  5. bhs guidelines 2004.boeh-ingel
  6. bhs guidelines 2004.boeh-ingel
  7. bhs guidelines 2004.boeh-ingel